What are the recommended genetic testing, counseling, and cancer surveillance strategies for individuals with suspected or confirmed Lynch syndrome?

Lynch Syndrome: Genetic Testing, Counseling, and Surveillance

Identification and Genetic Testing Strategy

All patients with newly diagnosed colorectal cancer or endometrial cancer at any age should undergo universal tumor screening with immunohistochemistry (IHC) for mismatch repair (MMR) proteins or microsatellite instability (MSI) testing to identify Lynch syndrome. 1

Tumor Testing Approach

• IHC testing evaluates for loss of MLH1, MSH2, MSH6, or PMS2 protein expression in tumor tissue 1
• If MLH1 loss is detected, reflex testing for BRAF V600E mutation or MLH1 promoter methylation must be performed to exclude sporadic tumors 2
• Loss of MSH2, MSH6, or PMS2—or MLH1 loss without methylation—warrants immediate germline genetic testing 2
• Universal screening has 95.1% sensitivity and 95.5% specificity, superior to clinical criteria alone 1

Germline Testing Protocol

• Genetic testing should begin with the gene most likely to harbor the mutation based on IHC results 1
• If IHC is uninformative, test MLH1 or MSH2 first, then MSH6 or PMS2 if no mutation is found 1
• Comprehensive germline analysis must include both DNA sequencing and assays for large-scale rearrangements 2
• Approximately 95% of relatives who receive genetic counseling proceed with genetic testing 1, 2

Family History Criteria for Testing

Even without universal tumor screening, genetic evaluation is indicated for:

• Any individual with colorectal or endometrial cancer diagnosed before age 50 1
• One first-degree relative with colorectal or endometrial cancer diagnosed before age 50 1, 2
• Two or more first- or second-degree relatives with Lynch-associated cancers, with at least one diagnosed before age 50 1
• Three or more first- or second-degree relatives with Lynch-associated cancers at any age 1

Critical pitfall: Approximately 68% of patients with Lynch syndrome do NOT meet Amsterdam II criteria, so family history alone should never exclude testing 3

---

Colorectal Cancer Surveillance

Colonoscopy should begin at age 20-25 years for MLH1 and MSH2 mutation carriers (or 2-5 years before the youngest family diagnosis if before age 25), and be repeated every 1-2 years. 1, 3, 4

Gene-Specific Modifications

• MSH6 and PMS2 carriers may delay colonoscopy initiation to age 30-35 years due to lower early cancer risk (<2% by age 40) 5
• Annual colonoscopy (every 1 year) is recommended for MLH1 and MSH2 carriers, particularly males aged 40-60 years 1
• Colonoscopic surveillance reduces colorectal cancer incidence by 62-77% and significantly reduces mortality 1, 3, 4

Colonoscopy Quality Measures

• Chromoendoscopy using indigo carmine or methylene blue should be considered to improve detection of subtle lesions 2, 4
• Withdrawal time and complete examination are critical given accelerated tumor growth in Lynch syndrome 2

---

Gynecological Cancer Surveillance for Women

Women with Lynch syndrome should begin annual endometrial sampling and transvaginal ultrasound at age 30-35 years. 1, 3, 2, 4

Surveillance Protocol

• Annual endometrial biopsy is the primary screening method, as transvaginal ultrasound alone has limited sensitivity 2
• If endometrial biopsy yields insufficient samples, repeat the procedure promptly 2
• Patients must be educated to report any abnormal uterine bleeding or postmenopausal bleeding immediately 2
• Endometrial cancer lifetime risk is 30-60% in Lynch syndrome, with higher adherence to surveillance in mutation-confirmed women 1, 2

Risk-Reducing Surgery

Prophylactic total abdominal hysterectomy with bilateral salpingo-oophorectomy should be discussed after childbearing is complete, typically between ages 35-40 years. 1, 2

• MLH1 carriers should consider surgery around age 40 due to higher early-onset endometrial and ovarian cancer risk 2
• PMS2 carriers may delay surgery until age 50 given more modest risk elevation (3.0% endometrial cancer risk by age 50) 2, 5
• In one retrospective study, no endometrial or ovarian cancers developed in 61 women who underwent risk-reducing surgery over 10 years, compared to 33% endometrial cancer and 5.5% ovarian cancer in those who declined 1
• Estrogen-only hormone replacement therapy until natural menopause age (~51 years) is strongly recommended following prophylactic oophorectomy 2

Critical pitfall: Hysterectomy without bilateral salpingo-oophorectomy is inadequate, as Lynch syndrome carriers have elevated ovarian cancer risk requiring oophorectomy 2

---

Extracolonic Cancer Surveillance

Gastric and Small Bowel Cancer

• Consider upper endoscopy (EGD) every 3-5 years starting at age 25-35 years for selected individuals, particularly those of Asian descent or families with gastric cancer 1, 3
• Test for and eradicate Helicobacter pylori in all mutation carriers, as gastric cancer risk varies from 2-4% in Western populations to 30% in Korean populations 3

Urinary Tract Cancer

• Annual urinalysis with cytology starting at age 25-35 years may be considered, particularly for MLH1, MSH2, or EPCAM mutation carriers 1, 3, 4
• MSH2 carriers have the highest urothelial cancer risk at 6.9% 3

Central Nervous System Cancer

• Annual physical and neurologic examination starting at age 25-30 years may be considered, though data supporting this practice are limited 1, 3

Pancreatic Cancer

• No routine surveillance is recommended for pancreatic cancer 1

---

Surgical Management of Colorectal Cancer

When colorectal cancer is diagnosed in a Lynch syndrome patient, subtotal colectomy with ileorectal anastomosis is a reasonable alternative to segmental resection. 1

• A decision analytic study suggested that subtotal colectomy in patients under age 47 with Lynch syndrome increased life expectancy by 1-2.3 years 1
• The choice between subtotal and segmental colectomy should consider age, metachronous cancer risk, and patient preference 1
• Risk-reducing gynecologic surgery should be coordinated with any planned colorectal surgery in women with Lynch syndrome 2

---

Chemoprevention

Aspirin chemoprevention is strongly recommended to reduce colorectal and other cancer risk, with daily aspirin (600 mg) reducing colorectal cancer risk by 44% in Lynch syndrome. 3, 2

• Aspirin use should preferably be within the context of a clinical trial (e.g., CaPP3) 2
• Combined oral contraceptives or progestin-only methods may provide protection against endometrial cancer, though evidence is limited 2

---

Genetic Counseling Essentials

Genetic counseling must be provided before and after genetic testing, and should never be delayed due to other medical considerations such as reproductive concerns. 2

Counseling Components

• Detailed personal and family history assessment 6
• Information on the disorder, genetic tests, and inheritance patterns 6
• Discussion of management, surveillance, and cancer prevention options 6
• Career planning, family planning, and psychosocial support 6
• Explanation that a negative genetic test is only informative if a mutation has been previously identified in the family 4

Family Testing

• First-degree relatives of an affected individual should be offered genetic counseling and testing 1
• If a first-degree relative is unavailable or unwilling, more distant relatives should be offered testing for the known mutation 1
• Testing should begin with an affected family member when possible to identify the disease-causing mutation 1, 4

---

Management of Mutation-Negative Individuals

Individuals who test negative for a known familial mutation should follow average-risk colorectal cancer screening guidelines. 1

• If no familial mutation is found despite clinical suspicion, tailored surveillance based on individual and family risk assessment is recommended 1
• Consider genetic testing of an affected family member if possible to find a disease-causing mutation 1
• About 45% of families meeting Amsterdam criteria do not have MMR gene mutations (Familial Colorectal Cancer Type X), with increased colorectal cancer risk but lower than Lynch syndrome 4

---

Critical Pitfalls to Avoid

• Do not delay genetic testing while waiting to reach screening age; testing should occur as soon as a strong family history is identified 3
• Do not rely solely on family history criteria, as the majority of Lynch syndrome patients do not meet Amsterdam II criteria 3
• Do not assume a negative genetic test excludes Lynch syndrome if clinical suspicion is high; consider tumor testing or testing of affected relatives 4
• Do not recommend prophylactic hysterectomy based solely on family history without genetic testing confirmation 2
• Do not overlook that approximately 20% of proven Lynch syndrome cases present after age 60 3